Compound 101, with X = (CH2)2, demonstrated notable efficacy against breast cancer (MCF7 “wild p53” and MDA-MB-231 “mutant p53”) cell lines (MTT assay, IC50 = 11.9 and 9.30 μM, respectively) [74] (Supplementary Figure S17). Here, TP53 is linked to breast carcinoma.